DK1406568T3 - Sekventielle lægemiddelafgivelsessystemer - Google Patents

Sekventielle lægemiddelafgivelsessystemer

Info

Publication number
DK1406568T3
DK1406568T3 DK02749899T DK02749899T DK1406568T3 DK 1406568 T3 DK1406568 T3 DK 1406568T3 DK 02749899 T DK02749899 T DK 02749899T DK 02749899 T DK02749899 T DK 02749899T DK 1406568 T3 DK1406568 T3 DK 1406568T3
Authority
DK
Denmark
Prior art keywords
active ingredient
drug delivery
delivery systems
absorption
dissolution
Prior art date
Application number
DK02749899T
Other languages
English (en)
Inventor
S Indiran Pather
John M Siebert
John Hontz
Original Assignee
Cima Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cima Labs Inc filed Critical Cima Labs Inc
Application granted granted Critical
Publication of DK1406568T3 publication Critical patent/DK1406568T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A61K9/025—Suppositories; Bougies; Bases therefor; Ovules characterised by shape or structure, e.g. hollow layered, coated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK02749899T 2001-07-10 2002-07-10 Sekventielle lægemiddelafgivelsessystemer DK1406568T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/901,983 US20030068356A1 (en) 2001-07-10 2001-07-10 Sequential drug delivery systems
PCT/US2002/021796 WO2003005944A1 (en) 2001-07-10 2002-07-10 Sequential drug delivery systems

Publications (1)

Publication Number Publication Date
DK1406568T3 true DK1406568T3 (da) 2007-10-01

Family

ID=25415151

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02749899T DK1406568T3 (da) 2001-07-10 2002-07-10 Sekventielle lægemiddelafgivelsessystemer

Country Status (10)

Country Link
US (3) US20030068356A1 (da)
EP (2) EP1818029B1 (da)
JP (1) JP4617081B2 (da)
AT (1) ATE363261T1 (da)
AU (2) AU2002320385B2 (da)
CA (1) CA2451106C (da)
DE (1) DE60220408T2 (da)
DK (1) DK1406568T3 (da)
ES (2) ES2286263T3 (da)
WO (1) WO2003005944A1 (da)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974590B2 (en) * 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
EP1449525A1 (en) * 2003-02-20 2004-08-25 Cross Chem Llc chewing gum in the form of multi-layer tablets
RS20060009A (sr) * 2003-07-11 2008-06-05 F.Hoffmann-La Roche Ag., Oralni oblik za doziranje sakvinavir mezilata
UA81335C2 (uk) * 2003-07-11 2007-12-25 Ф.Хоффманн-Ля Рош Аг Оральна дозована форма саквінавіру мезилату
KR101087464B1 (ko) 2003-08-08 2011-11-25 밸리언트 인터내셔널(바베이도스) 에스알엘 부프로피온 히드로클로라이드의 개질 방출형 정제
EP1708686B1 (en) 2003-12-31 2011-02-16 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
DE602004031771D1 (de) * 2003-12-31 2011-04-21 Cima Labs Inc Brauseformen von opiaten zur oralen anwendung und verfahren zur verabreichung von oxycodon
US7858121B2 (en) 2003-12-31 2010-12-28 Cima Labs, Inc. Effervescent oral fentanyl dosage form and methods of administering fentanyl
KR20130116378A (ko) 2004-02-17 2013-10-23 트랜스셉트 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의 사용 방법
US7615028B2 (en) * 2004-12-03 2009-11-10 Chf Solutions Inc. Extracorporeal blood treatment and system having reversible blood pumps
GB0509317D0 (en) * 2005-05-06 2005-06-15 Clarke Anthony Pharmaceutical formulation of apomorphine
US20060276501A1 (en) 2005-05-25 2006-12-07 Transoral Pharmaceuticals, Inc. Solid compositions for treating middle-of-the-night insomnia
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US9289583B2 (en) 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8252328B2 (en) 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
EP1980240A1 (en) * 2007-04-11 2008-10-15 Cephalon France Lyophilized pharmaceutical compositions and methods of making and using same
WO2009081411A2 (en) * 2007-12-26 2009-07-02 Rainbow Medical Nitric oxide generation to treat female sexual dysfunction
US20090198271A1 (en) * 2008-01-31 2009-08-06 Rainbow Medical Ltd. Electrode based filter
EA201100313A1 (ru) 2008-09-09 2011-10-31 Астразенека Аб Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
BRPI1010511A2 (pt) * 2009-04-09 2019-04-09 Alkermes Pharma Ireland Limited composição, e, métodos para tratar um paciente que sofre de esquizofrenia, e para reduzir o risco de comportamento suicida recorrente em um paciente com esquizofrenia ou desordem esquizoafetiva
PT2952191T (pt) * 2009-06-12 2018-11-30 Sunovion Pharmaceuticals Inc Apomorfina sublingual
CA2764963C (en) 2009-06-25 2016-11-01 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
WO2011025673A1 (en) * 2009-08-26 2011-03-03 Aptapharma, Inc. Multilayer minitablets
US20110202108A1 (en) * 2010-02-18 2011-08-18 Rainbow Medical Ltd. Electrical menorrhagia treatment
US8529914B2 (en) * 2010-06-28 2013-09-10 Richard C. Fuisz Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive
EP2651357B1 (en) 2010-12-16 2020-04-01 Sunovion Pharmaceuticals Inc. Sublingual films
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
DK2696687T3 (da) 2011-04-12 2017-02-06 Novo Nordisk As Dobbeltacylerede GLP-1 derivater
PH12014500316B1 (en) 2011-09-19 2018-10-03 Orexo Ab New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
BR112014016085A8 (pt) 2011-12-28 2017-07-04 Pozen Inc composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
EP4324475A1 (en) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
PL3542790T3 (pl) 2012-03-22 2024-02-26 Novo Nordisk A/S Kompozycje zawierające substancję dostarczającą i ich przygotowanie
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
JP6203816B2 (ja) 2012-03-29 2017-09-27 セラバイオーム，エルエルシー 回腸及び虫垂に対して活性の胃腸部位特異的経口ワクチン接種製剤
TR201815935T4 (tr) 2012-05-02 2018-11-21 Orexo Ab Akut ağrının tedavisi için yeni alfentanil bileşimi.
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
AU2014239883B2 (en) 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
KR20210086717A (ko) 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
US11058856B2 (en) 2014-12-23 2021-07-13 Acelrx Pharmaceuticals, Inc. Systems, devices and methods for dispensing oral transmucosal dosage forms
EP4578461A3 (en) 2015-04-21 2025-09-03 Sumitomo Pharma America, Inc. Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3131123A (en) 1959-03-13 1964-04-28 Lab Francais De Therapeutique Enteric tablets and manufacture thereof
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US4452808A (en) * 1982-12-07 1984-06-05 Smithkline Beckman Corporation 4-Aminoalkyl-2(3H)-indolones
US4756710A (en) * 1985-04-05 1988-07-12 Merck & Co., Inc. pH-Mediated drug delivery system
US4764375A (en) 1985-09-11 1988-08-16 Kv Pharmaceutical Company Sachet drug delivery system
GB8820327D0 (en) 1988-08-26 1988-09-28 May & Baker Ltd New compositions of matter
DE3838431A1 (de) * 1988-11-12 1990-05-17 Bayer Ag Ibuprofen-brausezubereitungen
ATE145551T1 (de) * 1989-10-02 1996-12-15 Cima Labs Inc Brausedosisform sowie verfahren zu deren verabreichung
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5102666A (en) * 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
TW212139B (da) * 1991-04-15 1993-09-01 Yamanouchi Pharma Co Ltd
US5503846A (en) * 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
IT1270831B (it) 1993-09-17 1997-05-13 Romano Deghenghi Composizioni farmaceutiche orali effervescenti contenenti estrone
AU676430B2 (en) * 1994-03-07 1997-03-06 Theratech, Inc. Drug-containing adhesive composite transdermal delivery device
CA2185803C (en) * 1994-03-18 2006-07-11 Edward M. Rudnic Emulsified drug delivery systems
JP3170139B2 (ja) 1994-04-08 2001-05-28 エスエス製薬株式会社 発泡性錠剤
CA2187023A1 (en) * 1994-04-13 1995-10-26 Steven Andrew Giannos Temporally controlled drug delivery systems
WO1995034291A1 (en) 1994-06-15 1995-12-21 Dumex-Alpharma A/S Pellets
GB9417524D0 (en) * 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
CA2160423A1 (en) * 1994-11-02 1996-05-03 Hemant N. Joshi Salts of nefazodone having improved dissolution rates
FR2732217B1 (fr) 1995-03-29 1997-06-06 Hesnard Xavier Forme d'administration solide a usage oral
GB9510830D0 (en) * 1995-05-27 1995-07-19 Zeneca Ltd Proteins
US5607697A (en) * 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
CA2236368C (en) 1995-11-06 2001-10-23 Somerset Pharmaceuticals, Inc. Sublingual and buccal administration of selegiline
CN1160079C (zh) 1998-03-11 2004-08-04 格勒兰制药株式会社 发泡性肠溶制剂
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
US20030118645A1 (en) 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US20030091629A1 (en) 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6200604B1 (en) * 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
DE19814257A1 (de) * 1998-03-31 1999-10-07 Asta Medica Ag Brauseformulierungen
US6312728B1 (en) * 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation
DE69942205D1 (de) 1998-08-13 2010-05-12 Cima Labs Inc Microemulsionen als feste dosisformen zur oralen verabreichung
WO2000035418A2 (en) * 1998-12-18 2000-06-22 Bayer Corporation Chewable drug delivery system
US6210699B1 (en) 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
US6326384B1 (en) * 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
DE602004031771D1 (de) 2003-12-31 2011-04-21 Cima Labs Inc Brauseformen von opiaten zur oralen anwendung und verfahren zur verabreichung von oxycodon
US7858121B2 (en) 2003-12-31 2010-12-28 Cima Labs, Inc. Effervescent oral fentanyl dosage form and methods of administering fentanyl
US20070036853A1 (en) 2003-12-31 2007-02-15 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
EP1708686B1 (en) 2003-12-31 2011-02-16 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering

Also Published As

Publication number Publication date
EP1406568A4 (en) 2004-12-15
WO2003005944A1 (en) 2003-01-23
US20030068356A1 (en) 2003-04-10
AU2008203464B2 (en) 2010-07-01
AU2002320385B2 (en) 2008-05-01
AU2008203464A1 (en) 2008-08-21
US20050031677A1 (en) 2005-02-10
ES2286263T3 (es) 2007-12-01
JP4617081B2 (ja) 2011-01-19
DE60220408D1 (de) 2007-07-12
DE60220408T2 (de) 2008-01-31
EP1818029A3 (en) 2008-06-11
EP1406568A1 (en) 2004-04-14
CA2451106C (en) 2009-12-22
EP1406568B1 (en) 2007-05-30
US20030232080A1 (en) 2003-12-18
ES2604780T3 (es) 2017-03-09
CA2451106A1 (en) 2003-01-23
US7670617B2 (en) 2010-03-02
JP2004534839A (ja) 2004-11-18
EP1818029B1 (en) 2016-09-07
EP1818029A2 (en) 2007-08-15
HK1106126A1 (en) 2008-03-07
ATE363261T1 (de) 2007-06-15

Similar Documents

Publication Publication Date Title
ATE363261T1 (de) Sequenzielles arzneimittelabgabesystem
ATE450252T1 (de) Arzneimittel-mikroteilchen
EP1585423A4 (en) SYSTEMS AND METHODS FOR HEALTH MONITORING AND TRANSDERMAL MEDICAMENT ISSUE
DE69919713D1 (de) Pharmazeutische zubereitung mit verzögerter wirkstofffreisetzung von phenytoin natrium
SE0102276D0 (sv) Device and method for the administration of a medicament
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
CY1109861T1 (el) Διαδερμικο θεραπευτικο συστημα για την ασθενεια του παρκινσον που προκαλει υψηλα επιπεδα πλασματος της ροτιγοτινης
DE60027921D1 (de) Vorrichtung zur gleichzeitigen verabreichung von gasen und medikamenten
BR0007974A (pt) Usos de um agente farmacologicamente ativo, deum constructo de gene e de um antìgeno, métodospara produzir uma composição farmacêutica em póe para administrar uma droga a um indivìduo emnecessidade dela, composição farmacêutica, formade dosagem unitária, e, artigo de manufatura parasuprimento transdérmico ou transmucoso de umagente farmacologicamente ativo a um indivìduo
DE60115029D1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
NO993520L (no) Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon
CY1107512T1 (el) Νεες υποκατεστημενες με βενζιμιδαζολιο μορφες δοσολογιας και μεθοδος για τη χρηση τους
MXPA02004235A (es) Dosificacion de farmacos a traves de la mucosa oral usando una solucion solida.
EE200200578A (et) Antihüpertensiivsete ja antiangiogeensete ainete terapeutilised kombinatsioonid
AR034213A1 (es) Composiciones de medicamentos sobre la base de agentes anticolinergicos e inhibidores de pde-iv
ATE292453T1 (de) Antivirale arznei
WO2002055098A3 (en) Latency associated peptide for providing latency to pharmaceutically active proteins
EA200600817A1 (ru) Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты)
EA200400557A1 (ru) Дозированная форма, устройство и способы лечения
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
NO20023464D0 (no) Sammensetning for intestinal avlevering
ATE464878T1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
EP1491210A4 (en) THERAPEUTIC MEDICAMENT USING ANTIBODY PRESENTING HOLES PROTEIN NANOTEHICLES AND HIGH PROTEIN NANOTEHICLES
ES2188513T3 (es) Utilizacion de desoxipeganina para el tratamiento de la drogodependencia.
BR0211323A (pt) Combinação de ingredientes ativos, uso de uma combinação de ingredientes ativos e método de terapia farmacológica de dependência de nicotina